Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in Refractory Metastatic Colorectal Cancer in Minority Populations
NCT06562543Phase 4Recruiting
- Sponsor
- Takeda
- Start
- Jan 2025
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Takeda. Primary endpoint: Treatment Emergent Grade 3 and Grade 4 Hypertension at 35 months. Started Jan 2025; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06562543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562543.